Related content

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

By Silver Richard T   Kiladjian Jean-Jacques   Hasselbalch Hans Carl  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 49-58

Informa Healthcare

Access to resources Recommend Favorite

Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients

By Chim C. S.   Sim J. P.   Chan C. C.   Kho B. C.   Chan J. C.   Wong L. G.   Law M.   Liang R.   Kwong Y. L.  

Hematology, Vol. 15, Iss. 4, 2010-08 ,pp. : 187-192

Maney Publishing

Access to resources Recommend Favorite

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

By Lee Yoo  

International Journal of Hematology, Vol. 97, Iss. 6, 2013-06 ,pp. : 804-807

Springer Publishing Company

Access to resources Recommend Favorite

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F

By Steimle C.   Lehmann U.   Temerinac S.   Goerttler Ph.   Kreipe H.   Meinhardt G.   Heimpel H.   Pahl H.  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 239-244

Springer Publishing Company

Access to resources Recommend Favorite

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders

By Basquiera Ana L.   Soria Néstor W.   Ryser Ricardo   Salguero Miriam   Moiraghi Beatriz   Sackmann Federico   Sturich Ana G.   Borello Adriana   Berretta Adriana   Bonafé Miriam   Barral José Moreno   Palazzo Emilio D.   García Juan J.  

Hematology, Vol. 14, Iss. 6, 2009-12 ,pp. : 323-330

Maney Publishing

Access to resources Recommend Favorite